title: Combined hepatitis B vaccines.
abstract: The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed. Data on the safety, immunogenicity, and European licensing status and availability of haxavalent vaccines combining hepatitis B (HepB), Haemophilus influenza type b (Hib), diphtheria, tetanus, and pertussis (acellular) (DTPa), and inactivated poliovirus (IPV) antigens were presented. Finally, the impact of the availability of combined hepatitis B vaccines on hepatitis B immunisation programmes in Europe were examined and the added value of combined hepatitis B vaccines globally was estimated.
authors.affiliation: World Health Organization, Via Appia 20, 1211 Geneva, Switzerland.
authors.forename: David
authors.initials: D
authors.lastname: FitzSimons
authors.forename: Guido
authors.initials: G
authors.lastname: François
authors.forename: Nedret
authors.initials: N
authors.lastname: Emiroğlu
authors.forename: Pierre
authors.initials: P
authors.lastname: Van Damme
mesh_terms: D002986:Clinical Trials as Topic; D004335:Drug and Narcotic Control; D017325:Hepatitis B Vaccines / Q000191:economics / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D008004:Licensure; D017778:Vaccines, Combined / Q000276:immunology
chemical_list: D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined